Healthcare

Osteopore Limited (ASX:OSX), a regenerative medicine company specialising in 3D-printed, bioresorbable implants, announced on 14 July 2025 that it has secured market approval for its products in Switzerland under the European Union’s Medical Device Regulation (MDR). The milestone triggered a sharp rise in investor …

Telix Pharmaceuticals Ltd (ASX:TLX; NASDAQ:TLX) has garnered bullish sentiment from major analysts, with multiple BUY ratings and significant upside potential. As of the latest update, the company’s current target price stands at AUD 33.84—representing a 40.77% upside from its last close at AUD 24.04.

Tissue Repair Limited (ASX:TRP) saw its share price rise more than 20% to AUD 0.26 on 11 July 2025 after announcing major commercial milestones, including new distribution partnerships and its move toward large-scale global expansion. The clinical-stage biotech company has signed a multi-year agreement …

Orthocell Limited(ASX:OCC) has announced its first U.S. sales revenue from its collagen-based nerve repair productRemplir™, marking a key commercial milestone just over three months after receiving U.S. FDA 510(k) clearance. This transition into revenue generation follows the product’s first surgical application in Ohio on …

Artrya Limited(ASX:AYA), an Australian medical technology company focused on coronary artery disease detection, has announced its first revenue from the U.S. market after securing a five-year agreement with Tanner Health. The deal marks a key milestone for Artrya’s commercial rollout of itsSalix® Coronary Anatomyplatform …

Shares ofImagion Biosystems Limited(ASX:IBX) surged nearly44%toAUD 0.018on Thursday morning after the company announced progress in its regulatory discussions with the U.S. Food and Drug Administration (FDA) regarding its upcomingPhase 2 HER2 breast cancer clinical trial.

Island Pharmaceuticals Limited (ASX:ILA)has entered into a binding asset purchase agreement to acquire the Galidesivir antiviral program from BioCryst Pharmaceuticals Inc. The acquisition follows a previously announced Letter of Intent in September 2024 and will add a second clinical-stage antiviral asset to Island’s portfolio.